Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dinaciclib + epirubicin
- Development stage
- Phase 1
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Dinaciclib + epirubicin is a combination therapy that was investigated for the treatment of metastatic triple-negative breast cancer (TNBC). Dinaciclib (SCH 727965) is a CDK1/CDK2 inhibitor, while epirubicin is an anthracycline chemotherapy agent. The combination was studied based on preclinical evidence showing that CDK inhibitors combined with anthracyclines were synergistic in decreasing viability of TNBC cell lines. The rationale was particularly relevant for TNBC cases with low molecular weight cyclin E (LMW-E) isoforms overexpression, which occurs in approximately 70% of TNBC cases.
- Other names
- dinaciclib + epirubicin hydrochloride
02
Targets
CDK1 (Cyclin-dependent kinase 1)CDK2 (Cyclin-dependent kinase 2)CDK5 (Cyclin-dependent kinase 5)CDK9 (Cyclin-dependent kinase 9)DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on dinaciclib + epirubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dinaciclib + epirubicin.